Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H889A
- Development stage
- Unknown
- Lead developer
- Jizhong Biological Technology
- Modality
- Small Molecules
- Administration
- Intravenous (injection)
01
Overview
H889A is an investigational drug developed by Huizhou Jizhong Biological Technology. It is currently in Phase 2 clinical trials for postoperative pain management, specifically for analgesia after thoracoscopic surgery under general anesthesia and after orthopedic procedures such as hallux valgus correction. The drug is administered by injection and has also been studied for its pharmacokinetics, safety, and tolerability in patients undergoing hepatobiliary surgery. The precise mechanism of action has not been disclosed publicly; available data focus on its use as a novel analgesic agent in the perioperative setting[1][5].
- Other names
- H889AH-889AH 889A
Beyond the preview
Go deeper on H889A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H889A.